NRX Pharmaceuticals Inc Forecast, price target & analysts
NRX Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation
NRX Pharmaceuticals Inc Classifications & Recommendation
NRX Pharmaceuticals Inc Price Target
| Target Price | $47.94 |
| Price | $3.00 |
| Potential |
1,500.67%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target NRX Pharmaceuticals Inc 2027 .
The average NRX Pharmaceuticals Inc target price is $47.94.
This is
1,500.67%
register free of charge
$51.45
1,617.86%
register free of charge
$10.10
237.23%
register free of charge
|
|
| A rating was issued by 11 analysts: 10 Analysts recommend NRX Pharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the NRX Pharmaceuticals Inc stock has an average upside potential 2027 of
1,500.67%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.23 | 60.57 |
| 4,824.23% | ||
| EBITDA Margin | -1,310.57% | -25.26% |
| 98.07% | ||
| Net Margin | -2,326.83% | 30.24% |
| 101.30% |
7 Analysts have issued a sales forecast NRX Pharmaceuticals Inc 2026 . The average NRX Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an NRX Pharmaceuticals Inc EBITDA forecast 2026. The average NRX Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 NRX Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average NRX Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.34 | 0.42 |
| 43.22% | 131.34% | |
| P/E | 7.06 | |
| EV/Sales | 1.71 |
7 Analysts have issued a NRX Pharmaceuticals Inc forecast for earnings per share. The average NRX Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
NRX Pharmaceuticals Inc...
Current NRX Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BTIG |
Locked
➜
Locked
|
Locked | Sep 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 25 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| BTIG |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | May 05 2026 |
| Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 27 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BTIG:
Locked
➜
Locked
|
Sep 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 25 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
BTIG:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
May 05 2026 |
|
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 27 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
